Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sei Iwai

Clinical Cardiac Electrophysiology Hawthorne, NY Medical Doctor

NPI 1033206115 CMS profile 273995

19 Bradhurst Ave, Suite 3850S, Hawthorne, NY 10532

Open in the dashboard

General payments

$53,323

211 records reported · program years 2019–2025

Research payments

$27,866

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$72,788 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Sei Iwai of Hawthorne, NY is reported in the CMS Open Payments database as having received $53,323 across 211 general payments and $27,866 in research payments paid to them. Separately, studies naming them as principal investigator received $72,788 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 85th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,969 46
2025 Research $27,770 1
2024 General $10,291 48
2024 Research $96 1
2023 General $4,660 25
2022 General $1,583 23
2021 General $5,351 17
2020 General $455 7
2019 General $20,015 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sei Iwai
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Sei Iwai were reported at $10,969. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Sei Iwai Clinical Cardiac Electrophysiology median Middle half National median
2019 $20,015 $2,361 $585–$8,260 $163
2020 $455 $993 $247–$4,351 $114
2021 $5,351 $1,185 $326–$4,739 $132
2022 $1,583 $2,073 $554–$6,789 $149
2023 $4,660 $2,568 $759–$8,159 $160
2024 $10,291 $2,557 $703–$7,403 $164
2025 $10,969 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biotronik Inc. $26,425 53 payments
  2. Janssen Pharmaceuticals, Inc $10,376 15 payments
  3. Biosense Webster, Inc. $4,028 46 payments
  4. Medtronic, Inc. $2,233 18 payments
  5. AltaThera Pharmaceuticals LLC $2,040 2 payments
  6. Boston Scientific Corporation $1,821 17 payments
  7. CardioFocus, Inc. $1,389 1 payment
  8. Medical Device Business Services, Inc. $839 4 payments
  9. Abiomed $646 10 payments
  10. Vektor Medical Inc. $605 2 payments
  11. Other $2,921 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $13,773 38 payments
  2. Food and Beverage $10,424 154 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,950 6 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $7,600 5 payments
  5. Consulting Fee $6,375 5 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $6,200 3 payments
Products named General payments · program years 2019–2025
  1. XARELTO $10,376 15 payments
  2. Carto 3 $4,052 25 payments
  3. Rivacor $3,869 5 payments
  4. Edora $3,869 5 payments
  5. Acticor $3,869 5 payments
  6. Sentus $2,687 3 payments
  7. Plexa $2,687 3 payments
  8. Sotalol Hydrochloride $2,040 2 payments
  9. Iforia; Linoxsmart; Setrox; $1,500 2 payments
  10. Solia $1,182 2 payments
  11. Other $8,500 108 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Vektor Medical Inc. $27,770 1 payment
  2. Abiomed $96 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

203

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$87,928

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

37.4%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 34 $42,941
Multaq Dronedarone Hcl Brand 28 $24,554
Xarelto Rivaroxaban Brand 14 $16,675
Flecainide Acetate Generic 61 $2,207
Dofetilide Generic 16 $910
Metoprolol Succinate Generic 50 $641

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$133,924

Medicare's payments for the services billed

Medicare patients

913

Average age 76

Services billed

2,246

415 women, 498 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Atrial fibrillation 54%
Arthritis 48%
Diabetes 45%
Heart failure 44%
Chronic kidney disease 38%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sotalol Hydrochloride
  • AltaThera Pharmaceuticals LLC $2,040
$2,040 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

213 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record